Skip to main content

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date   Total number of shares Total number of voting rights03/31/2026   296,042,447     Total gross of voting rights: 296,042,447    Total net* of voting rights: 295,914,379  * Net total = total number of voting rights attached to shares – shares without voting rightsAttachmentPDF Version

Continue reading

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth – ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) (the Company) today announced the closing of its acquisition of Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular and hepatic and renal disease. “The closing of this acquisition marks an important milestone in advancing our Vision 2040 and strengthens our commitment to delivering differentiated therapies that address the growing global burden of cardiometabolic disease,” said Sheldon Koenig, President and...

Continue reading

KBR’s Mission Technology Solutions Supports NASA’s Artemis II Mission as Astronauts Embark on Historic Return to the Moon

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) — KBR‘s (NYSE: KBR) Mission Technology Solutions business is delivering critical services to support astronauts on NASA’s Artemis II mission as they embark on their journey around the moon – the first human mission beyond low-Earth orbit since Apollo 17 in 1972. From inside Mission Control, KBR teams are providing real-time monitoring and control of spacecraft systems and astronaut health, helping to ensure crew safety and the success of this landmark endeavor. KBR teams are working alongside NASA throughout mission execution, supporting the crew during their 10-day journey. The work is being performed under longstanding KBR contracts that support NASA’s human spaceflight portfolio. “Artemis II highlights the durability and strategic importance of KBR’s human spaceflight portfolio,” said...

Continue reading

American Assets Trust, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Information

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) — American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its first quarter 2026 earnings in a press release to be issued after the market closes on Tuesday, April 28, 2026. Senior management will hold a conference call for its first quarter 2026 earnings on Wednesday, April 29, 2026 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust, Inc. Conference Call. A live on-demand audio webcast of the conference call will be available on the “Investor Relations” section of the Company’s website at www.americanassetstrust.com. A replay webcast will be available on the Company’s website approximately one hour after the conclusion of the conference call. About American Assets Trust, Inc. American Assets...

Continue reading

Alerus Financial Corporation to Announce First Quarter Financial Results on Wednesday, April 29

MINNEAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) — Alerus Financial Corporation (Nasdaq: ALRS) announced that it will issue its first quarter financial results on Wednesday, April 29, 2026. Alerus Financial Corporation will also host a conference call at 11:00 a.m. Central Time on Thursday, April 30, 2026, to discuss its financial results. Analysts and institutional investors may participate in the question-and-answer session. Attendees are encouraged to register ahead of time for the call. Conference Call Information Date: Thursday, April 30, 2026 Time: 12:00 p.m. Eastern Time / 11:00 a.m. Central Time Register: https://register-conf.media-server.com/register/BIff30a6d15e4e4b268617d2f78268fe7e A recording of the call and transcript will be available at investors.alerus.com following the call. About Alerus Financial Corporation Alerus...

Continue reading

Riot Announces First Quarter 2026 Production and Operations Updates

CASTLE ROCK, Colo., April 02, 2026 (GLOBE NEWSWIRE) — Riot Platforms, Inc. (NASDAQ: RIOT) (“Riot” or “the Company”), a Bitcoin-driven industry leader in the development of large-scale data centers and bitcoin mining applications, announces unaudited production and operations updates for the first quarter of 2026.   Bitcoin Production and Operations Updates for Q1 2026        Comparison (%)Metric   Q1 2026 1 Q1 2025 1 Quarter/QuarterBitcoin Produced   1,473 1,530 -4%Average Bitcoin Produced per Day   16.4 17.0 -4%Bitcoin Held 2   15,680 3 19,223 -18%Bitcoin Sold   3,778 – N/ABitcoin Sales – Net Proceeds   $289.5 million – N/AAverage Net Price per Bitcoin Sold   $76,626 N/A N/ADeployed Hash Rate – Total 2   42.5 E+H/s 33.7 E+H/s 26%Avg. Operating Hash Rate – Total 4   36.4...

Continue reading

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka’s bempedoic acid products, together with related milestone payments, subject to a cap, for total consideration of $50 million Athyrium Funds to receive tiered royalties ranging from 12% to 33%, as well as milestone payments, until receiving aggregate payments equal to 2.0x their investment, after which all rights revert to Esperion Financing supports Esperion’s acquisition of Corstasis Therapeutics Inc., which developed and is commercializing Enbumyst™, the first FDA-approved intranasal loop diuretic for treatment of edema associated with cardiovascular and hepatic and renal diseaseNEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) — Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR)...

Continue reading

Century Aluminum Applauds President Trump for Executive Order to Fully Enforce Sec. 232 Aluminum Tariffs

CHICAGO, April 02, 2026 (GLOBE NEWSWIRE) — Century Aluminum Company (NASDAQ: CENX) is applauding President Donald Trump’s new executive order that will close valuation loopholes that importers have been using to avoid the President’s tariffs on steel and aluminum, leveling the playing field for American manufacturers. The Section 232 tariff on primary aluminum is unchanged and remains at 50 percent. Importers had been abusing valuation loopholes to reduce their liability under the President’s steel and aluminum tariffs. In some instances, importers declared only the value of raw steel and aluminum while excluding value added through processing, thereby lowering the tariff owed and disadvantaging domestic manufacturers. The order clarifies that importers must declare the full value of covered products, promoting consistent enforcement...

Continue reading

Nextensa obtains permit for Lake Side project

Lake SideLake Side – Tour & Taxis, BrusselsNON-REGULATED INFORMATION Brussels, 02/04/2026 Nextensa obtains permit for Lake Side project Nextensa obtained the urban planning permit for the Lake Side project on 2 April 2026, marking the final phase of the sustainable urban development of the Tour & Taxis site. The approval confirms that the project meets all requirements and represents a milestone in the development of the last zone. The granting of the permit follows a permitting process that began in March 2023. After addressing the requirements formulated by two consultation committees, and taking into account the comments, concerns, and wishes of local residents and authorities, a new, revised application was submitted in December 2025. “Obtaining the permit for Lake Side is an important milestone for the continued...

Continue reading

Roundtable CEO James Heckman Clarifies Equity Status, Announces One Year Lock

Ryvyl Adds Veteran former Goldman Sachs Tech Banker Steve Fletcher to Board of DirectorsIn photo: James Heckman, Roundtable Founder and CEO  Seattle, WA, April 02, 2026 (GLOBE NEWSWIRE) — James Heckman, CEO of AI-driven, Web3 media platform – RTB Digital, Inc. (dba “Roundtable”), following shareholder approval of the company’s merger with RYVYL Inc. (NASDAQ: RVYL) outlined the post-merger capitalization table lock-up agreement, and related liquidity considerations; provided additional detail on the recently announced $10 million deposit toward a strategic investment and partnership; and announced a veteran digital media-focused board member. Heckman announced, “about 85% of outstanding shares, including new shares from the merger, and 100% of the $35 million recently invested, which auto-converts into equity – concurrent...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.